RLYBHIGH SIGNALRISK10-K

RLYB has substantially narrowed its focus to RLYB116 as its lead program while abandoning RLYB212, signaling a major strategic pivot amid ongoing profitability challenges and Nasdaq delisting concerns.

The removal of all references to RLYB212 (anti-HPA-1a antibody for FNAIT prevention) and exclusive focus on RLYB116 (C5 inhibitor) represents a fundamental shift in the company's pipeline strategy. The addition of explicit Nasdaq delisting warnings and going concern language around capital access indicates heightened financial distress, despite improved current-period losses.

Comparing 2026-03-16 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

RLYB showed meaningful improvement in key loss metrics, with net losses substantially reduced and R&D expenses meaningfully lower year-over-year, while revenue grew modestly. Operating cash flow also improved notably, and the company reduced both current and total liabilities by roughly one-third. However, these improvements appear driven more by cost-cutting and pipeline prioritization rather than operational success, as evidenced by the strategic abandonment of one of their two lead programs.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+84.5%
-$57.8M→-$9.0M

Net income grew 84.5% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
-52.8%
$41.5M→$19.6M

R&D spending cut 52.8% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+45.3%
-$60.5M→-$33.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
+43%
$600K→$858K

Strong top-line growth of 43% — accelerating demand or successful expansion into new markets.

Operating Cash Flow
Cash Flow
+39.5%
-$49.3M→-$29.8M

Operating cash flow surged 39.5% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
-33.3%
$6.5M→$4.3M

Liabilities reduced 33.3% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-32.3%
$6.2M→$4.2M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-13
ADDED
We are not currently profitable, and we may never achieve or sustain profitability; If we continue to progress the development of our product candidates, we will require significant additional capital to fund our operations.
If we continue to progress the development of our product candidates and fail to obtain necessary financing, we may not be able to complete the development or commercialization of RLYB116 or any other product candidate.
Given our limited resources and access to capital, we may decide to prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business; Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our intellectual property or product candidates; Our failure to meet the listing standards of the Nasdaq Stock Market LLC, ("Nasdaq"), could result in the delisting of our common stock.
Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired; We are heavily dependent on the success of RLYB116, which is in early-stage clinical development.
We must be able to successfully identify patients and capture a significant market share to achieve profitability and growth; We face significant competition from biotechnology and pharmaceutical companies, and if we continue to progress the development of our product candidates, our operating results will suffer if we fail to compete effectively; If we continue to progress the development of our product candidates, we may pursue business development transactions and collaborate with third parties for the development and commercialization of our product candidates.
+7 more — sign up free →
REMOVED
These risks include the following: We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the foreseeable future.
We are not currently profitable, and we may never achieve or sustain profitability; We will require significant additional capital to fund our operations.
If we fail to obtain necessary financing, we may not be able to complete the development or commercialization of RLYB212, RLYB116 or any other product candidate.
We must be able to successfully identify patients and capture a significant market share to achieve profitability and growth; The FDA, EMA or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests, including RLYB212.
Since our launch in January 2018, we have built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →